The firm is now consulting with experts to evaluate detection of enteroviruses and rhinoviruses in respiratory specimens for its next-generation ePlex system.
The company aims to seek US and European approval later this year.
The investment bank maintained its stock ratings for Hologic, Cepheid, and T2 Biosystems.
The self-contained, cartridge-based test runs on the firm's GeneXpert system.
The company is using a $3 million, three-year grant to clinically validate the test, which it hopes will be the first of its kind approved by the FDA.
In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.
George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.
A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.
The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.